"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

More information: Jennifer Kern Sliwa et al, Effects of esketamine nasal spray on depressive symptom severity in adults with ...

Manufacturer Janssen says Esketamine can lift a patient's mood within 24 hours of use. The drug is intended for patients who have not responded to two other, conventional antidepressants which can ...

Esketamine, the S isomer of ketamine, has already gained approval for treatment-resistant depression under the trademark Spravato; psilocybin and ketamine have been shown to provide benefits to ...

Yesterday, the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from a head-to-head study with a long-acting ...

Mental health is a vital aspect of overall well-being, especially for students who face unique pressures and challenges. From ...

Initial studies demonstrating rapid antidepressant effects drove research leading to the recent US Food and Drug Administration (FDA) approval of intranasal esketamine, the first (and at present, only ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.